BE2016C023I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2016C023I2 BE2016C023I2 BE2016C023C BE2016C023C BE2016C023I2 BE 2016C023 I2 BE2016C023 I2 BE 2016C023I2 BE 2016C023 C BE2016C023 C BE 2016C023C BE 2016C023 C BE2016C023 C BE 2016C023C BE 2016C023 I2 BE2016C023 I2 BE 2016C023I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03027511 | 2003-11-28 | ||
| EP04803302A EP1691833B1 (en) | 2003-11-28 | 2004-11-26 | Compositions comprising polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2016C023I2 true BE2016C023I2 (en:Method) | 2023-12-18 |
Family
ID=34626385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2016C023C BE2016C023I2 (en:Method) | 2003-11-28 | 2016-05-10 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10000574B2 (en:Method) |
| EP (2) | EP1691833B1 (en:Method) |
| AT (1) | ATE459374T1 (en:Method) |
| AU (1) | AU2004293182B2 (en:Method) |
| BE (1) | BE2016C023I2 (en:Method) |
| CA (1) | CA2544532C (en:Method) |
| CY (2) | CY1110689T1 (en:Method) |
| DE (1) | DE602004025840D1 (en:Method) |
| DK (1) | DK1691833T3 (en:Method) |
| ES (1) | ES2341252T3 (en:Method) |
| FR (1) | FR16C1000I2 (en:Method) |
| HU (1) | HUS1600019I1 (en:Method) |
| LU (1) | LU93067I2 (en:Method) |
| NL (1) | NL300807I2 (en:Method) |
| PL (1) | PL1691833T3 (en:Method) |
| PT (1) | PT1691833E (en:Method) |
| SI (1) | SI1691833T1 (en:Method) |
| WO (1) | WO2005052004A2 (en:Method) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2658557C (en) | 2006-08-14 | 2015-12-01 | Xencor, Inc. | Optimized antibodies that target cd19 |
| DK2066349T3 (da) * | 2006-09-08 | 2012-07-09 | Medimmune Llc | Humaniseret anti-cd19-antistoffer og anvendelse heraf i behandling af tumorer, transplantation og autoimmune sygdomme |
| US9308257B2 (en) * | 2007-11-28 | 2016-04-12 | Medimmune, Llc | Protein formulation |
| US8658765B2 (en) | 2009-12-31 | 2014-02-25 | Avidbiotics Corp. | Non-natural MIC proteins |
| US8796420B2 (en) | 2009-12-31 | 2014-08-05 | Avidbiotics Corp. | Non-natural MIC proteins |
| EP3412687B1 (en) | 2010-10-27 | 2020-03-18 | Amgen Research (Munich) GmbH | Methods for treating dlbcl |
| DK2686020T3 (en) | 2011-03-17 | 2017-05-01 | Univ Birmingham | REDIRECTED IMMUNTERY |
| RU2632647C2 (ru) | 2011-04-22 | 2017-10-06 | Аптево Рисерч Энд Девелопмент Ллс | Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| EP3680254A1 (en) | 2013-12-17 | 2020-07-15 | F. Hoffmann-La Roche AG | Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies |
| EP3083690A1 (en) | 2013-12-17 | 2016-10-26 | F.Hoffmann-La Roche Ag | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
| SG10201913324PA (en) | 2014-05-29 | 2020-03-30 | Macrogenics Inc | Tri-specific binding molecules and methods of use thereof |
| KR102709593B1 (ko) | 2014-11-05 | 2024-09-26 | 제넨테크, 인크. | 박테리아 내 2쇄 단백질을 생산하는 방법 |
| EP3753948A1 (en) | 2014-11-05 | 2020-12-23 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
| JP2018508481A (ja) | 2015-02-02 | 2018-03-29 | ザ ユニバーシティ オブ バーミンガム | 複数のｔ細胞エピトープを有する標的化部分ペプチドエピトープ複合体 |
| KR20180013881A (ko) | 2015-05-29 | 2018-02-07 | 제넨테크, 인크. | 암에서의 pd-l1 프로모터 메틸화 |
| CN116327953A (zh) | 2015-06-17 | 2023-06-27 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法 |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| EP3377103B2 (en) | 2015-11-19 | 2025-03-12 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| JP7325186B2 (ja) | 2015-12-09 | 2023-08-14 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗薬物抗体の形成を減少させるためのｉｉ型抗ｃｄ２０抗体 |
| EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
| CN108368179B (zh) | 2016-01-08 | 2022-08-23 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法 |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| AU2018276419A1 (en) | 2016-06-02 | 2019-10-17 | F. Hoffmann-La Roche Ag | Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer |
| US11046776B2 (en) | 2016-08-05 | 2021-06-29 | Genentech, Inc. | Multivalent and multiepitopic antibodies having agonistic activity and methods of use |
| JP7250674B2 (ja) | 2016-08-08 | 2023-04-03 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療及び診断方法 |
| MX2019006955A (es) | 2016-12-19 | 2019-08-01 | Hoffmann La Roche | Terapia de combinacion con agonistas de 4-1bb orientados (cd137). |
| MX2019006954A (es) | 2016-12-20 | 2019-08-01 | Hoffmann La Roche | Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137). |
| BR112020007630A2 (pt) | 2017-11-01 | 2020-11-17 | F. Hoffmann-La Roche Ag | anticorpo biespecífico ox40, produto farmacêutico, composição farmacêutica e anticorpos biespecíficos anti-fap/ anti-ox40 |
| PL3765489T3 (pl) | 2018-03-13 | 2025-02-10 | F. Hoffmann-La Roche Ag | Terapeutyczne połączenie agonistów 4-1BB z przeciwciałami anty-CD20 |
| TWI841551B (zh) | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | 使用靶向4-1bb (cd137)之促效劑的組合療法 |
| CA3102562A1 (en) * | 2018-06-07 | 2019-12-12 | Cullinan Management, Inc. | Multi-specific binding proteins and methods of use thereof |
| AU2019342133B8 (en) | 2018-09-21 | 2025-08-07 | Genentech, Inc. | Diagnostic methods for triple-negative breast cancer |
| CN113260626B (zh) | 2018-11-05 | 2024-09-13 | 豪夫迈·罗氏有限公司 | 在原核宿主细胞中产生双链蛋白质的方法 |
| WO2020221792A1 (en) | 2019-04-30 | 2020-11-05 | Amgen Research (Munich) Gmbh | Means and methods of treating burkitt lymphoma or leukemia |
| KR20230031981A (ko) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| EP3972998A1 (en) | 2019-05-21 | 2022-03-30 | Novartis AG | Cd19 binding molecules and uses thereof |
| CA3161283A1 (en) | 2019-12-11 | 2021-06-17 | Cullinan Oncology, Inc. | Anti-cd19 antibodies and multi-specific binding proteins |
| AU2021287998A1 (en) | 2020-06-11 | 2023-02-02 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| WO2021257503A1 (en) | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Methods and compositions for treating triple-negative breast cancer |
| KR102453073B1 (ko) * | 2020-08-14 | 2022-10-11 | 건국대학교 글로컬산학협력단 | 피키아 파스토리스를 이용한 이중특이적 항체의 제조방법 및 이에 따른 이중특이적 항체 |
| CA3209479A1 (en) | 2021-02-03 | 2022-08-11 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| JP7717832B2 (ja) | 2021-04-10 | 2025-08-04 | ジェンマブ エー／エス | Ｆｏｌｒ１結合剤、そのコンジュゲートおよびこれを使用する方法 |
| US20250066490A1 (en) | 2021-04-23 | 2025-02-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
| WO2022228706A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
| AU2021443318A1 (en) | 2021-04-30 | 2023-09-07 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| EP4083061A1 (en) * | 2021-04-30 | 2022-11-02 | Kilometro Rosso SPA | Fusion proteins and use thereof in the treatment of membranous nephropathy |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| EP4496631A1 (en) | 2022-03-23 | 2025-01-29 | F. Hoffmann-La Roche AG | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
| KR20250004776A (ko) | 2022-04-13 | 2025-01-08 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이성 항체의 약학 조성물 및 사용 방법 |
| WO2024030956A2 (en) | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Cd39-specific binding agents and methods of using the same |
| CN120152989A (zh) | 2022-11-03 | 2025-06-13 | 豪夫迈·罗氏有限公司 | 抗cd19/抗cd28双特异性抗体的组合疗法 |
| WO2024243423A1 (en) | 2023-05-24 | 2024-11-28 | Mozart Therapeutics, Inc. | Cd8-specific binding proteins and methods of using the same |
| WO2024261013A1 (en) | 2023-06-21 | 2024-12-26 | F. Hoffmann-La Roche Ag | Combination therapy with fap-targeted lymphotoxin beta receptor agonists |
| US20250115680A1 (en) | 2023-09-26 | 2025-04-10 | Profoundbio Us Co. | Ptk7 binding agents, conjugates thereof and methods of using the same |
| WO2025137344A1 (en) | 2023-12-20 | 2025-06-26 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rβ) and related methods |
| US20250296992A1 (en) | 2024-01-10 | 2025-09-25 | Genmab A/S | Slitrk6 binding agents, conjugates thereof and methods of using the same |
| WO2025181219A1 (en) | 2024-02-29 | 2025-09-04 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
| WO2025222129A2 (en) | 2024-04-19 | 2025-10-23 | Mozart Therapeutics, Inc. | Engineered cytokines and targeted cytokine delivery |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| DE69233068T2 (de) | 1991-02-27 | 2004-01-22 | Micromet Ag | Serin-reiche peptidlinker |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US5656730A (en) * | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| PL199747B1 (pl) | 1998-04-21 | 2008-10-31 | Micromet Ag | Jednołańcuchowy wielofunkcyjny polipeptyd, polinukleotyd, wektor, komórka, sposób wytwarzania polipeptydu, kompozycja, zastosowanie polipeptydu lub wektora lub polinukleotydu i zastosowanie polinukleotydu lub wektora oraz sposób identyfikacji aktywatorów lub inhibitorów aktywacji lub stymulacji komórek T |
| US20020142964A1 (en) * | 2000-11-02 | 2002-10-03 | Nissen Torben Lauesgaard | Single-chain polypeptides |
| IL161677A0 (en) * | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
-
2004
- 2004-11-26 WO PCT/EP2004/013445 patent/WO2005052004A2/en not_active Ceased
- 2004-11-26 EP EP04803302A patent/EP1691833B1/en not_active Expired - Lifetime
- 2004-11-26 US US10/580,660 patent/US10000574B2/en active Active
- 2004-11-26 AT AT04803302T patent/ATE459374T1/de active
- 2004-11-26 PT PT04803302T patent/PT1691833E/pt unknown
- 2004-11-26 ES ES04803302T patent/ES2341252T3/es not_active Expired - Lifetime
- 2004-11-26 PL PL04803302T patent/PL1691833T3/pl unknown
- 2004-11-26 EP EP10155222A patent/EP2186527A1/en not_active Withdrawn
- 2004-11-26 DK DK04803302.1T patent/DK1691833T3/da active
- 2004-11-26 AU AU2004293182A patent/AU2004293182B2/en not_active Expired
- 2004-11-26 CA CA2544532A patent/CA2544532C/en not_active Expired - Lifetime
- 2004-11-26 SI SI200431360T patent/SI1691833T1/sl unknown
- 2004-11-26 DE DE602004025840T patent/DE602004025840D1/de not_active Expired - Lifetime
-
2010
- 2010-05-27 CY CY20101100465T patent/CY1110689T1/el unknown
-
2016
- 2016-05-03 NL NL300807C patent/NL300807I2/nl unknown
- 2016-05-05 CY CY2016010C patent/CY2016010I2/el unknown
- 2016-05-05 HU HUS1600019C patent/HUS1600019I1/hu unknown
- 2016-05-10 BE BE2016C023C patent/BE2016C023I2/fr unknown
- 2016-05-11 LU LU93067C patent/LU93067I2/fr unknown
- 2016-05-20 FR FR16C1000C patent/FR16C1000I2/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004025840D1 (de) | 2010-04-15 |
| AU2004293182A1 (en) | 2005-06-09 |
| SI1691833T1 (sl) | 2010-06-30 |
| ATE459374T1 (de) | 2010-03-15 |
| CY1110689T1 (el) | 2015-06-10 |
| CY2016010I1 (el) | 2016-08-31 |
| EP1691833A2 (en) | 2006-08-23 |
| HUS1600019I1 (hu) | 2016-06-28 |
| PT1691833E (pt) | 2010-06-08 |
| ES2341252T3 (es) | 2010-06-17 |
| FR16C1000I2 (fr) | 2017-02-03 |
| CA2544532C (en) | 2015-06-16 |
| EP2186527A1 (en) | 2010-05-19 |
| WO2005052004A2 (en) | 2005-06-09 |
| CA2544532A1 (en) | 2005-06-09 |
| PL1691833T3 (pl) | 2010-08-31 |
| LU93067I2 (fr) | 2016-07-11 |
| EP1691833B1 (en) | 2010-03-03 |
| WO2005052004A3 (en) | 2006-03-09 |
| DK1691833T3 (da) | 2010-05-03 |
| AU2004293182B2 (en) | 2010-02-18 |
| US10000574B2 (en) | 2018-06-19 |
| NL300807I2 (en:Method) | 2016-10-13 |
| US20070249529A1 (en) | 2007-10-25 |
| CY2016010I2 (el) | 2016-08-31 |
| FR16C1000I1 (en:Method) | 2016-06-24 |